Neubase Therapeutics Stock Probability of Future Stock Price Finishing Over 12.9
NBSE Stock | USD 0.44 0.02 4.76% |
NeuBase |
NeuBase Therapeutics Target Price Odds to finish over 12.9
The tendency of NeuBase Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current Price | Horizon | Target Price | Odds to move over $ 12.90 or more in 90 days |
0.44 | 90 days | 12.90 | close to zero percent |
Based on a normal probability distribution, the odds of NeuBase Therapeutics to move over $ 12.90 or more in 90 days from now is close to zero percent (This NeuBase Therapeutics probability density function shows the probability of NeuBase Stock to fall within a particular range of prices over 90 days) . Probability of NeuBase Therapeutics price to stay between its current price of $ 0.44 and $ 12.90 at the end of the 90-day period is about 87.35 .
Given the investment horizon of 90 days NeuBase Therapeutics has a beta of -0.59. This indicates as returns on the benchmark increase, returns on holding NeuBase Therapeutics are expected to decrease at a much lower rate. During a bear market, however, NeuBase Therapeutics is likely to outperform the market. Additionally NeuBase Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite. NeuBase Therapeutics Price Density |
Price |
Predictive Modules for NeuBase Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NeuBase Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NeuBase Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NeuBase Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. NeuBase Therapeutics is not an exception. The market had few large corrections towards the NeuBase Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NeuBase Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NeuBase Therapeutics within the framework of very fundamental risk indicators.α | Alpha over NYSE Composite | -0.11 | |
β | Beta against NYSE Composite | -0.59 | |
σ | Overall volatility | 0.21 | |
Ir | Information ratio | -0.03 |
NeuBase Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NeuBase Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NeuBase Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.NeuBase Therapeutics generated a negative expected return over the last 90 days | |
NeuBase Therapeutics has high historical volatility and very poor performance | |
NeuBase Therapeutics has some characteristics of a very speculative penny stock | |
NeuBase Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (33.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
NeuBase Therapeutics currently holds about 29.85 M in cash with (29.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
NeuBase Therapeutics has a poor financial position based on the latest SEC disclosures | |
Roughly 13.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from globenewswire.com: NeuBase Therapeutics Announces Receipt of Notice from Nasdaq |
NeuBase Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NeuBase Stock often depends not only on the future outlook of the current and potential NeuBase Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NeuBase Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 1.6 M | |
Cash And Short Term Investments | 23.2 M |
NeuBase Therapeutics Technical Analysis
NeuBase Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. NeuBase Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of NeuBase Therapeutics. In general, you should focus on analyzing NeuBase Stock price patterns and their correlations with different microeconomic environments and drivers.
NeuBase Therapeutics Predictive Forecast Models
NeuBase Therapeutics' time-series forecasting models is one of many NeuBase Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary NeuBase Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about NeuBase Therapeutics
Checking the ongoing alerts about NeuBase Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for NeuBase Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
NeuBase Therapeutics generated a negative expected return over the last 90 days | |
NeuBase Therapeutics has high historical volatility and very poor performance | |
NeuBase Therapeutics has some characteristics of a very speculative penny stock | |
NeuBase Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (33.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
NeuBase Therapeutics currently holds about 29.85 M in cash with (29.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
NeuBase Therapeutics has a poor financial position based on the latest SEC disclosures | |
Roughly 13.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from globenewswire.com: NeuBase Therapeutics Announces Receipt of Notice from Nasdaq |
Check out NeuBase Therapeutics Backtesting, NeuBase Therapeutics Valuation, NeuBase Therapeutics Correlation, NeuBase Therapeutics Hype Analysis, NeuBase Therapeutics Volatility, NeuBase Therapeutics History as well as NeuBase Therapeutics Performance. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.60) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.